Mogamulizumab (MOG) is a humanized monoclonal anti-C–C chemokine receptor type 4 (CCR4) antibody, which has been demonstrated to be clinically effective for ATLL [13–15]. Here, CCR4 is linked to adult T-cell leukemia/lymphoma.